RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Homozygous Familial Hypercholesterolaemia: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Clinical observation of a patient with malignant progression of homozygous familial hypercholesterolemia
K. R. Mikava et al., Therapy (5 October 2026)
https://doi.org/10.18565/therapy.2026.7.97-102
- 2.
A striking lipid phenotype: A case of homozygous familial hypercholesterolemia
Murshida Rahman Rumi et al., Journal of Association of Clinical Endocrinologist and Diabetologist of Bangladesh (5 October 2026)
https://doi.org/10.3329/jacedb.v5i20.93989
- 3.
Expanding the LDL-C criterion for suspected homozygous familial hypercholesterolemia to include treated and imputed elevations.
John Mancini G B et al., Journal of clinical lipidology (24 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42838768/
- 4.
Real-World Outcomes of Lipoprotein Apheresis in Homozygous Familial Hypercholesterolemia: A Single-Center Longitudinal Experience.
Mercan Sarıdaş Filiz et al., Journal of clinical medicine (17 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42796005/
- 5.
Expectations for Angiopoietin-like 3 Inhibitors Taking Broad Lipid-modifying Effects on the Comprehensive Control of Atherosclerotic Cardiovascular Disease Risk in Patients with Homozygous Familial Hypercholesterolemia.
Yoshida Hiroshi, Journal of atherosclerosis and thrombosis (11 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42732948/
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT07491172 · Recruiting · Phase 1 · CRISPR Therapeutics AG
Ages 18 to 75
https://clinicaltrials.gov/study/NCT07491172
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Homozygous Familial Hypercholesterolaemia
Homozygous familial hypercholesterolaemia is a rare inherited condition in which faulty genes on both copies severely limit the body's ability to clear LDL cholesterol from the blood. Very high cholesterol from birth can lead to fatty deposits in the skin and tendons and to early heart and blood vessel disease. Management uses intensive cholesterol-lowering medicines, sometimes with lipoprotein apheresis, alongside lifelong specialist monitoring.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Homozygous Familial Hypercholesterolaemia?
Homozygous familial hypercholesterolaemia is a rare inherited condition in which faulty genes on both copies severely limit the body's ability to clear LDL cholesterol from the blood. Very high cholesterol from birth can lead to fatty deposits in the skin and tendons and to early heart and blood vessel disease. Management uses intensive cholesterol-lowering medicines, sometimes with lipoprotein apheresis, alongside lifelong specialist monitoring.
How many clinical trials are available for Homozygous Familial Hypercholesterolaemia?
RareWays currently indexes 53 clinical trials for Homozygous Familial Hypercholesterolaemia, of which 8 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Homozygous Familial Hypercholesterolaemia come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Homozygous Familial Hypercholesterolaemia.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.